BD Pharmingen™ Purified Mouse Anti-Human p53

p53

Mouse BALB/c IgG2a, κ

Human p53

The gene for the nuclear phosphoprotein p53 is the most commonly mutated gene yet identified in human cancers. Missense mutations occur in tumors of the colon, lung, breast, ovary, bladder and several other organs. The mutant p53 is overexpressed in a variety of transformed cells and wild-type p53 forms specific complexes with several viral oncogenes including SV40 large T, E1B from adenovirus, and E6 from human papilloma virus. Wild type p53 plays a role as a checkpoint protein for DNA damage during the G1/S-phase of the cell cycle. However, it is still unclear, whether point mutated forms of p53 are simple null mutants and/or dominant negatively acting proteins. DO-1 reacts with human wild-type and mutant p53. It cross-reacts with bovine p53 but does not cross-react with mouse or rat p53. DO-1 recognizes an epitope between amino acids 1 and 45 of all known forms of human p53. Human recombinant p53 protein was used as immunogen.

DO-1 The gene for the nuclear phosphoprotein p53 is the most commonly mutated gene yet identified in human cancers. Missense mutations occur in tumors of the colon, lung, breast, ovary, bladder and several other organs. The mutant p53 is overexpressed in a variety of transformed cells and wild-type p53 forms specific complexes with several viral oncogenes including SV40 large T, E1B from adenovirus, and E6 from human papilloma virus. Wild type p53 plays a role as a checkpoint protein for DNA damage during the G1/S-phase of the cell cycle. However, it is still unclear, whether point mutated forms of p53 are simple null mutants and/or dominant negatively acting proteins. DO-1 reacts with human wild-type and mutant p53. It cross-reacts with bovine p53 but does not cross-react with mouse or rat p53. DO-1 recognizes an epitope between amino acids 1 and 45 of all known forms of human p53. Human recombinant p53 protein was used as immunogen.

Mouse BALB/c IgG2a, κ

克隆 DO-1 (RUO)

0.5 mg/ml

Western blot (Routinely Tested), Immunohistochemistry-formalin (antigen retrieval required), Immunohistochemistry-frozen, Immunoprecipitation (Tested During Development)

Human (QC Testing), Cow (Tested in Development)

p53

Aqueous buffered solution containing ≤0.09% sodium azide.

研发参考(7) 1. Bartkova J, Bartek J, Vojtesek B, et al. Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. Eur J Cancer. 1993; 29A(6):881-886. (Clone-specific: Immunohistochemistry). 2. Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer. 1993; 72(12):3641-3647. (Clone-specific: Immunohistochemistry). 3. Girinsky T, Koumenis C, Graeber TG, Peehl DM, Giaccia AJ. Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res. 1995; 55(17):3726-3731. (Clone-specific: Western blot). 4. Jacquemier J, Moles JP, Penault-Llorca F, et al. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer. 1994; 69(5):846-852. (Clone-specific: Immunohistochemistry). 5. Vogelstein B. Cancer. A deadly inheritance. Nature. 1990; 348(6303):681-682. (Biology). 6. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods. 1992; 151(1-2):237-244. (Clone-specific: Immunohistochemistry, Immunoprecipitation, Western blot). 7. Xerri L, Bouabdallah R, Camerlo J, Hassoun J. Expression of the p53 gene in Hodgkin's disease: dissociation between immunohistochemistry and clinicopathological data. Hum Pathol. 1994; 25(5):449-454. (Clone-specific: Immunohistochemistry).